Threshold Pharmaceuticals Inc. (THLD) Drops 9.48% on February 03

Equities Staff |

Threshold Pharmaceuticals Inc. (THLD) was one of the Russell 2000's biggest losers for Wednesday February 03 as the stock slid 9.48% to $0.28, a loss of $-0.0294 per share. Starting at an opening price of $0.34 a share, the stock traded between $0.27 and $0.34 over the course of the trading day. Volume was 702,396 shares over 1,431 trades, against an average daily volume of 1.47 million shares and a total float of 71.46 million.

The losses send Threshold Pharmaceuticals Inc. down to a market cap of $20.05 million. In the last year, Threshold Pharmaceuticals Inc. has traded between $5.28 and $0.29, and its 50-day SMA is currently $1.15 and 200-day SMA is $3.38.

Threshold Pharmaceuticals Inc is a biotechnology company. It is engaged in discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer.

Threshold Pharmaceuticals Inc. is based out of South San Francisco, CA and has some 64 employees. Its CEO is Harold E. Selick.

For a complete fundamental analysis analysis of Threshold Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for THLD. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…